View ValuationShin Nippon Biomedical Laboratories 将来の成長Future 基準チェック /06Shin Nippon Biomedical Laboratories利益と収益がそれぞれ年間0.01%と10.2%増加すると予測されています。EPS は年間 減少すると予想されています。自己資本利益率は 3 年後に9.3% 0.3%なると予測されています。主要情報0.01%収益成長率-0.33%EPS成長率Life Sciences 収益成長17.0%収益成長率10.2%将来の株主資本利益率9.30%アナリストカバレッジLow最終更新日29 May 2026今後の成長に関する最新情報お知らせ • Feb 02Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the year ending March 31, 2024. For the period, the company expects revenue of ¥26,190 million, Operating profit of ¥3,470 million, Profit attributable to owners of parent of ¥3,975 million or ¥95.47 basic per share.すべての更新を表示Recent updatesお知らせ • Jun 17Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2027 Results on Aug 05, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2027 results on Aug 05, 2026お知らせ • May 11Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026.お知らせ • May 09Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2026 Results on May 11, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2026 results on May 11, 2026お知らせ • May 02Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026. Agenda: To change the Company's representatives and to assign executive members as described below; and to consider AGM.お知らせ • Dec 10Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2026 Results on Feb 06, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026お知らせ • Aug 16Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2026 Results on Nov 07, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2026 results on Nov 07, 2025お知らせ • Jun 13Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2026 Results on Aug 05, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2026 results on Aug 05, 2025お知らせ • May 08Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2025Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2025.お知らせ • May 01Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of MigraineSatsuma Pharmaceuticals Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved a 505(b)(2) New Drug Application (NDA) for Atzumi™ (dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi was previously known as STS101. It is the second leading cause of disability worldwide in terms of time lost to disability and most common cause of disability among young women. The product is designed to provide patients an easy-to-use and easy-to-carry treatment option. The FDA approval for Atzumi is based on two clinical studies (Phase 1 PK trial and ASCEND Phase 3 open-label, long-term safety trial), which demonstrated fast absorption, rapid achievement of high DHE plasma concentrations, and sustained DHE plasma levels over time as well as safety and tolerability in subjects with migraine.お知らせ • Mar 05Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2025 Results on May 08, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2025 results on May 08, 2025お知らせ • Dec 19Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2025 Results on Feb 05, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2025 results on Feb 05, 2025お知らせ • Nov 26Satsuma Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories, Ltd. Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine with or Without AuraSatsuma Pharmaceuticals, Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. announced that the U.S. Food and Drug Administration (FDA) has accepted for review a resubmission to original new drug application (NDA) for the investigational product STS101 (dihydroergotamine nasal powder) for the acute treatment of migraine with or without aura as a complete response to their January 2024 action letter. The Prescription Drug User Fee Act (PDUFA) date is set as April 30, 2025. Almost 40 million people in the United States suffer from migraine, especially among working women in their 20s to 40s. The U.S. market for acute migraine medications is estimated to be over USD 1.0 Billion.お知らせ • Sep 19Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2025 Results on Nov 06, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2025 results on Nov 06, 2024お知らせ • Jul 12Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2025 Results on Aug 06, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2025 results on Aug 06, 2024お知らせ • May 10Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024.お知らせ • Mar 02Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2024 Results on May 08, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2024 results on May 08, 2024お知らせ • Feb 02Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the year ending March 31, 2024. For the period, the company expects revenue of ¥26,190 million, Operating profit of ¥3,470 million, Profit attributable to owners of parent of ¥3,975 million or ¥95.47 basic per share.お知らせ • Dec 06Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2024 Results on Feb 02, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2024 results on Feb 02, 2024お知らせ • Nov 07Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending 2024Shin Nippon Biomedical Laboratories, Ltd. announced that it was resolved at its Board of Directors' meeting November 7, 2023 that interim dividends of ¥20.00 shall be paid from retained earnings to shareholders on the record date of September 30, 2023. Effective date November 30, 2023.For the year ending 2024, the company expects to pay a dividend of JPY 30.00 per share.お知らせ • Aug 30Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2024 Results on Nov 07, 2023Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023お知らせ • Jun 17Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific MeetingSatsuma Pharmaceuticals Inc. and its corporate parent, Shin Nippon Biomedical Laboratories Ltd. announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society's (AHS) 65th Annual Scientific Meeting. The 2023 meeting will be held in a hybrid virtual and in-person format at the JW Marriott in Austin, Texas from June 15 to June 18, 2023. Full abstracts are now available on the AHS website and will be published in the journal Headache®?.お知らせ • Jun 09Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers.Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers for $27.6 million on April 16, 2023. Under the terms of the transaction SNBL will acquire all the remaining shares of common stock of Satsuma through a tender offer, for a price of $0.91 per share in cash. In addition, SNBL will issue one non-tradeable CVR, represents the right to additional payments of up to $5.77 per share, in total in the event where Satsuma’s STS101 is approved by the FDA and commercialized, and SNBL achieves cumulative financial return objectives of up to $500 million. The purchase price will be funded from existing cash. Post the completion of the transaction, SNBL will hold 100% stake in Satsuma. The merger agreement also provides that the payment of a $905,136 termination fee will be payable by Satsuma to Shin Nippon. As part of the merger, Satsuma will terminate the employment of each of John Kollins, President and Chief Executive Officer of the Company, and Tom O’Neil, Chief Financial Officer of the Company, effective as of the closing of the Offer. Prior to the closing, such executive officers shall remain in their current positions with their current compensation.The transaction is subject to the tender of a majority of Satsuma’s outstanding shares, minimum cash condition and other customary closing conditions. The transaction has been unanimously approved by the Board of Directors of both SNBL and Satsuma. The tender offer period is planned from April 2023 to May 2023, with the initial period of the tender offer to commence within 15 business days following the execution of definitive agreement. The expiration of the tender offer is on June 5, 2023. American Stock Transfer & Trust Company acted as transfer agent and depository bank to Satsuma. Joshua M. Dubofsky of Latham & Watkins LLP acted as legal advisor to Satsuma. Ian B. Edvalson of Wilson Sonsini Goodrich & Rosati P.C. acted as legal advisor to Wilson Sonsini Goodrich & Rosati P.C. Lazard acted as lead financial advisor and Houlihan Lokey Capital, Inc. acted as financial advisor and fairness opinion provider to Satsuma. D.F. King & Co., Inc. acted as information agent to Satsuma.Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers on June 8, 2023. The Offer expired at the end of June 5, 2023. Total of 21,979,704 Shares were validly tendered and not validly withdrawn pursuant to the Offer, which represented approximately 66.0618% of the fully-diluted capitalization of Satsuma.業績と収益の成長予測OTCPK:SBLO.F - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202945,0444,501-477,30223/31/202840,9604,008-2,4846,32323/31/202738,3713,950-4,3346,23723/31/202632,5254,5672,9918,327N/A12/31/202531,3743,990N/AN/AN/A9/30/202534,6714,6542,0888,623N/A6/30/202533,3425,063N/AN/AN/A3/31/202532,4134,924-3,8977,035N/A12/31/202430,7014,942N/AN/AN/A9/30/202427,0743,896-11,7241,650N/A6/30/202426,1954,280N/AN/AN/A3/31/202426,4505,531-6,4982,106N/A12/31/202326,7035,503N/AN/AN/A9/30/202326,6264,607-4,0741,899N/A6/30/202326,8485,489N/AN/AN/A3/31/202325,0906,060-9504,004N/A12/31/202221,1736,231N/AN/AN/A9/30/202220,1358,0434,3827,170N/A6/30/202218,7537,245N/AN/AN/A3/31/202217,7487,1274,3395,952N/A12/31/202117,6367,432N/AN/AN/A9/30/202116,0686,0254,0755,301N/A6/30/202114,9784,844N/AN/AN/A3/31/202115,1103,6613,6294,746N/A12/31/202014,9102,421N/AN/AN/A9/30/202015,1752,8121,3892,706N/A6/30/202015,0043,234N/AN/AN/A3/31/202014,5612,5501,7883,018N/A12/31/201913,4971,990N/AN/AN/A9/30/201913,1671,915N/A2,988N/A6/30/201914,6761,524N/AN/AN/A3/31/201915,6581,950N/A2,892N/A12/31/201817,337-49N/AN/AN/A9/30/201817,928-993N/A2,943N/A6/30/201816,937-2,566N/AN/AN/A3/31/201816,600-3,555N/A1,344N/A12/31/201717,186-1,072N/AN/AN/A9/30/201717,714327N/A280N/A6/30/201717,230260N/AN/AN/A3/31/201717,244-915N/A-849N/A12/31/201615,880-1,821N/AN/AN/A9/30/201615,269-1,273N/A-3,109N/A6/30/201614,922-1,475N/AN/AN/A3/31/201614,7502,646N/A-3,339N/A12/31/201515,6372,060N/AN/AN/A9/30/201516,344401N/A-2,379N/A6/30/201517,1641,546N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SBLO.Fの予測収益成長率 (年間0.01% ) は 貯蓄率 ( 3.5% ) を下回っています。収益対市場: SBLO.Fの収益 ( 0.01% ) US市場 ( 18.5% ) よりも低い成長が予測されています。高成長収益: SBLO.Fの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: SBLO.Fの収益 ( 10.2% ) US市場 ( 12.6% ) よりも低い成長が予測されています。高い収益成長: SBLO.Fの収益 ( 10.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SBLO.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 9.3 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/29 10:33終値2026/06/09 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Shin Nippon Biomedical Laboratories, Ltd. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Yuki TsukamotoBofA Global ResearchAkitada IwasaDaiwa Securities Co. Ltd.Stephen BarkerJefferies LLC3 その他のアナリストを表示
お知らせ • Feb 02Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the year ending March 31, 2024. For the period, the company expects revenue of ¥26,190 million, Operating profit of ¥3,470 million, Profit attributable to owners of parent of ¥3,975 million or ¥95.47 basic per share.
お知らせ • Jun 17Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2027 Results on Aug 05, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2027 results on Aug 05, 2026
お知らせ • May 11Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026.
お知らせ • May 09Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2026 Results on May 11, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2026 results on May 11, 2026
お知らせ • May 02Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026. Agenda: To change the Company's representatives and to assign executive members as described below; and to consider AGM.
お知らせ • Dec 10Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2026 Results on Feb 06, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026
お知らせ • Aug 16Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2026 Results on Nov 07, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2026 results on Nov 07, 2025
お知らせ • Jun 13Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2026 Results on Aug 05, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2026 results on Aug 05, 2025
お知らせ • May 08Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2025Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2025.
お知らせ • May 01Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of MigraineSatsuma Pharmaceuticals Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved a 505(b)(2) New Drug Application (NDA) for Atzumi™ (dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi was previously known as STS101. It is the second leading cause of disability worldwide in terms of time lost to disability and most common cause of disability among young women. The product is designed to provide patients an easy-to-use and easy-to-carry treatment option. The FDA approval for Atzumi is based on two clinical studies (Phase 1 PK trial and ASCEND Phase 3 open-label, long-term safety trial), which demonstrated fast absorption, rapid achievement of high DHE plasma concentrations, and sustained DHE plasma levels over time as well as safety and tolerability in subjects with migraine.
お知らせ • Mar 05Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2025 Results on May 08, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2025 results on May 08, 2025
お知らせ • Dec 19Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2025 Results on Feb 05, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2025 results on Feb 05, 2025
お知らせ • Nov 26Satsuma Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories, Ltd. Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine with or Without AuraSatsuma Pharmaceuticals, Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. announced that the U.S. Food and Drug Administration (FDA) has accepted for review a resubmission to original new drug application (NDA) for the investigational product STS101 (dihydroergotamine nasal powder) for the acute treatment of migraine with or without aura as a complete response to their January 2024 action letter. The Prescription Drug User Fee Act (PDUFA) date is set as April 30, 2025. Almost 40 million people in the United States suffer from migraine, especially among working women in their 20s to 40s. The U.S. market for acute migraine medications is estimated to be over USD 1.0 Billion.
お知らせ • Sep 19Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2025 Results on Nov 06, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2025 results on Nov 06, 2024
お知らせ • Jul 12Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2025 Results on Aug 06, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2025 results on Aug 06, 2024
お知らせ • May 10Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024.
お知らせ • Mar 02Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2024 Results on May 08, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2024 results on May 08, 2024
お知らせ • Feb 02Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the year ending March 31, 2024. For the period, the company expects revenue of ¥26,190 million, Operating profit of ¥3,470 million, Profit attributable to owners of parent of ¥3,975 million or ¥95.47 basic per share.
お知らせ • Dec 06Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2024 Results on Feb 02, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2024 results on Feb 02, 2024
お知らせ • Nov 07Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending 2024Shin Nippon Biomedical Laboratories, Ltd. announced that it was resolved at its Board of Directors' meeting November 7, 2023 that interim dividends of ¥20.00 shall be paid from retained earnings to shareholders on the record date of September 30, 2023. Effective date November 30, 2023.For the year ending 2024, the company expects to pay a dividend of JPY 30.00 per share.
お知らせ • Aug 30Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2024 Results on Nov 07, 2023Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023
お知らせ • Jun 17Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific MeetingSatsuma Pharmaceuticals Inc. and its corporate parent, Shin Nippon Biomedical Laboratories Ltd. announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society's (AHS) 65th Annual Scientific Meeting. The 2023 meeting will be held in a hybrid virtual and in-person format at the JW Marriott in Austin, Texas from June 15 to June 18, 2023. Full abstracts are now available on the AHS website and will be published in the journal Headache®?.
お知らせ • Jun 09Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers.Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers for $27.6 million on April 16, 2023. Under the terms of the transaction SNBL will acquire all the remaining shares of common stock of Satsuma through a tender offer, for a price of $0.91 per share in cash. In addition, SNBL will issue one non-tradeable CVR, represents the right to additional payments of up to $5.77 per share, in total in the event where Satsuma’s STS101 is approved by the FDA and commercialized, and SNBL achieves cumulative financial return objectives of up to $500 million. The purchase price will be funded from existing cash. Post the completion of the transaction, SNBL will hold 100% stake in Satsuma. The merger agreement also provides that the payment of a $905,136 termination fee will be payable by Satsuma to Shin Nippon. As part of the merger, Satsuma will terminate the employment of each of John Kollins, President and Chief Executive Officer of the Company, and Tom O’Neil, Chief Financial Officer of the Company, effective as of the closing of the Offer. Prior to the closing, such executive officers shall remain in their current positions with their current compensation.The transaction is subject to the tender of a majority of Satsuma’s outstanding shares, minimum cash condition and other customary closing conditions. The transaction has been unanimously approved by the Board of Directors of both SNBL and Satsuma. The tender offer period is planned from April 2023 to May 2023, with the initial period of the tender offer to commence within 15 business days following the execution of definitive agreement. The expiration of the tender offer is on June 5, 2023. American Stock Transfer & Trust Company acted as transfer agent and depository bank to Satsuma. Joshua M. Dubofsky of Latham & Watkins LLP acted as legal advisor to Satsuma. Ian B. Edvalson of Wilson Sonsini Goodrich & Rosati P.C. acted as legal advisor to Wilson Sonsini Goodrich & Rosati P.C. Lazard acted as lead financial advisor and Houlihan Lokey Capital, Inc. acted as financial advisor and fairness opinion provider to Satsuma. D.F. King & Co., Inc. acted as information agent to Satsuma.Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers on June 8, 2023. The Offer expired at the end of June 5, 2023. Total of 21,979,704 Shares were validly tendered and not validly withdrawn pursuant to the Offer, which represented approximately 66.0618% of the fully-diluted capitalization of Satsuma.